Group 1 - The core viewpoint of the article highlights the performance and investment strategy of the AI Fund Dongcai Vision Growth Mixed Initiation A (018088), which reported a profit of 652,900 yuan in Q2 2025, with a net value growth rate of 7.02% [2][3] - The fund focuses on long-term investments in pharmaceutical and medical stocks, with a unit net value of 0.866 yuan as of July 18 [2][3] - The fund manager, Sun Chenyang, oversees two funds that have both achieved positive returns over the past year, with the Dongcai Excellence Growth Mixed Initiation A showing the highest growth rate of 51.42% [2][3] Group 2 - The fund's management indicated a strategic shift towards the innovative drug industry chain, emphasizing the potential of AI in drug development, disease diagnosis, and surgical treatment [3] - AI's role in enhancing the accuracy and efficiency of medical diagnoses and treatments is noted, with expectations for increased investment in AI pharmaceuticals and medical applications [3] - The fund's recent performance metrics show a three-month net value growth rate of 23.86%, a six-month growth rate of 36.14%, and a one-year growth rate of 50.53%, positioning it favorably among comparable funds [3] Group 3 - As of June 27, the fund's Sharpe ratio since inception is 0.0874, indicating its risk-adjusted return [7] - The maximum drawdown since inception is reported at 48.55%, with the largest quarterly drawdown occurring in Q1 2024 at 30.58% [11] - The fund has maintained an average stock position of 92.39% since inception, with a peak of 94.38% in H1 2024 [14] Group 4 - As of Q2 2025, the fund's total assets amount to 9.6956 million yuan [16] - The top ten holdings of the fund include companies such as MicroPort Medical, Hongbo Pharmaceutical, and Tigermed, reflecting its focus on the healthcare sector [19]

Group 1 - Sanbo Brain Science (301293.SZ) released its 2024 annual report on April 18, 2025, with 69 institutional investors holding a total of 54.79 million A-shares, accounting for 26.60% of the total share capital [1] - The top ten institutional investors include TBP 3Doctors (HK) Limited, various products from Taikang Life Insurance Co., Ltd., and others, with a combined holding ratio of 25.80%, which decreased by 5.34 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, 61 new public funds were disclosed this period, including Southern CSI 1000 ETF and others, while one public fund, Dongcai Yuanjian Growth Mixed Initiation A, was no longer disclosed [2] - In the insurance capital sector, two insurance funds reduced their holdings compared to the previous quarter, while one new insurance investor was disclosed, namely Taikang Life Insurance Co., Ltd. - Dividend - Personal Dividend - 019L-FH002 [2]